Author

Cathal Harmon

Primary ORCID profile (0000-0001-6728-910X · 3 papers)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Cathal HarmoniD3 papers · Moderna Therapeutics (United States)

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

Alexandra Ardaseva· 1 shared Davide Maestrini· 1 shared Derek Park· 1 shared Drew Williamson· 1 shared Hung Khong· 1 shared Jeffrey West· 1 shared Kimberly Luddy· 1 shared Mark Robertson-Tessi· 1 shared

Activity by Year

2018-2018 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alexandra Ardaseva

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Evolutionary exploitation of PD-L1 expression in hormone receptor positive breast cancer

Jeffrey West, Derek Park, Cathal Harmon, Drew Williamson, Peter Ashcroft, Davide Maestrini, Alexandra Ardaseva, Rafael Bravo, Prativa Sahoo, Hung Khong, Kimberly Luddy, Mark Robertson-Tessi

The paper models how timing of aromatase inhibitor and immune checkpoint inhibitor therapies affects tumor burden and metastatic potential in hormone receptor positive breast cancer.

bioRxiv · Oct 26, 2018 · PreprintCancer Biology